Skip to main content
BRNS logo

Barinthus Biotherapeutics plc

BRNSNASDAQHealthcareBiotechnology

$0.74Today:- (-)1Y −44.44%

As of Sep 18, 2026 close

Market cap
$30.23M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.51$1.50
Volume (live)
-
Avg. volume (3M)
68.23K

Barinthus Biotherapeutics (BRNS) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Barinthus Biotherapeutics used $47.98M of cash in operating activities and spent $37.00K on capital expenditures. That left free cash flow of −$48.02M.

Barinthus Biotherapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Barinthus Biotherapeutics plc (BRNS) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-66.46-61.18-73.635.32-51.11-17.71-20.82
Depreciation & Amortization5.855.800.004.320.600.210.35
Deferred Income Tax-0.18-0.04-3.09-4.34-0.120.000.00
Stock Based Compensation0.474.715.069.8816.493.630.00
Change in Working Capital-0.362.606.17-5.52-7.181.922.94
Change in Accounts Receivable6.421.305.67-5.830.560.48-0.96
Change in Inventory0.000.000.00-0.65-4.150.000.00
Change in Accounts Payable-2.200.90-3.381.14-3.530.592.98
Change in Other Working Capital3.412.363.88-0.18-8.560.890.92
Other Operating Activities3.412.3614.57-24.098.620.92-1.23
Net Cash from Operating Activities-47.98-28.94-50.93-14.43-32.58-11.03-18.76
Investing Activities
Capital Expenditures-0.04-0.89-5.41-6.14-1.15-0.29-0.13
Acquisitions0.450.000.000.39-11.770.002.06
Other Investing Activities0.000.00-5.410.000.000.000.00
Net Cash from Investing Activities0.42-0.89-5.41-5.75-12.91-0.291.93
Financing Activities
Debt Repayment0.000.000.00-0.160.0041.240.00
Common Stock Issued0.002.162.040.48100.610.000.00
Other Financing Activities0.00-1.79-0.160.00-5.270.190.00
Net Cash from Financing Activities0.002.161.870.33222.7441.440.00
Summary
Effect of Forex Changes on Cash7.01-2.022.170.19-6.461.7228.26
Net Change in Cash-40.55-29.69-52.30-19.67170.7931.8311.43
Cash at Beginning of Period112.40142.09194.39214.0543.2711.430.00
Cash at End of Period71.85112.40142.09194.39214.0543.2711.43
Free Cash Flow-48.02-29.83-56.34-20.57-33.73-11.32-18.89
Supplemental Disclosures
Interest Paid----1.840.00-
Income Taxes Paid----0.15--

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Barinthus Biotherapeutics Cash Flow

What is Barinthus Biotherapeutics's free cash flow?

Barinthus Biotherapeutics had negative free cash flow of $48.02M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$47.98M minus $37.00K of capital expenditures.

How much does Barinthus Biotherapeutics spend on capital expenditures?

Barinthus Biotherapeutics spent $37.00K on capital expenditures in fiscal 2025, compared with $892.00K a year earlier.

Does Barinthus Biotherapeutics pay dividends or buy back shares?

Barinthus Biotherapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition